Pleasanton, California – Federal research grants came with an eligibility requirement that a Pleasanton biotech company allegedly failed to meet: its principal investigator could not hold another full-time job. Cyion Technologies LLC has now agreed to pay $528,335.74 to settle allegations that it improperly obtained and used that funding.
The dispute spans three National Institutes of Health awards and grant applications submitted six years apart. Federal officials alleged that Cyion failed to disclose its principal investigator’s outside full-time employment when applying for the awards and later drawing down the money.
Cyion, which works in biological research and drug discovery, received two Small Business Technology Transfer grants and one Small Business Innovation Research grant. The settlement resolves allegations that the company violated the False Claims Act by accepting and drawing funds from awards it was ineligible to receive.
According to the government, the terms governing those awards barred companies from applying for or receiving funding when their principal investigators held outside full-time employment. That restriction was central to the allegations against Cyion.
The company applied for the two STTR grants in 2017 and drew down funds through 2019. It applied for the SBIR grant in 2023 and drew down funds through 2024. The United States alleged that Cyion did not disclose its principal investigator’s outside full-time employment during the relevant application and funding periods.
“NIH small business research grants are intended to fuel innovation, not reward companies that break the rules,” said United States Attorney Craig H. Missakian.
“The requirements governing these grants, including restrictions on outside full-time employment, are not optional. When companies misrepresent their eligibility to obtain federal funding, my office will vigorously enforce the False Claims Act to hold them accountable and protect taxpayer dollars.”
The investigation and settlement were a joint effort by the U.S. Attorney’s Office for the Northern District of California and the U.S. Department of Health and Human Services Office of Inspector General. Assistant U.S. Attorney Savith Iyengar handled the matter for the government.
“Cyion Technologies’ failure to disclose its principal investigator’s outside full-time employment undermined the purpose of federal small business research grants,” said Robb R. Breeden, Special Agent in Charge of HHS-OIG’s Pacific Regional Office. “These programs exist to support eligible innovators conducting critical scientific research – not to provide funding to entities that misrepresent their eligibility.”
Federal officials described the case as part of their work to combat fraud involving federal grants, with the False Claims Act serving as a key enforcement tool. The payment resolves the government’s allegations concerning Cyion’s eligibility for the three NIH awards.
Anyone with information about suspected fraud, waste, abuse or mismanagement involving HHS programs can submit tips and complaints through the HHS-OIG reporting page.